Showing 9251-9260 of 10530 results for "".
- OXY Unveils Overhauled Acne Lineshttps://practicaldermatology.com/news/20130507-oxy_unveils_overhauled_acne_lines/2459550/After 30 years, the OXY brand (Mentholatum Company) has had a makeover and now offers two distinct lines grouped by active ingredients designed to either kill acne (benzoyl peroxide) or provide maintenance for acne-prone skin (salicylic acid). The OXY Maximum Action line includes, among others, OXY
- Pliaglis Launches in Europehttps://practicaldermatology.com/news/20130502-pliaglis_launches_in_europe/2459551/Nuvo Research Inc. and Galderma Pharma, S.A. launched Pliaglis (lidocaine and tetracaine) Cream 7%/7% in Europe. Nuvo has licensed worldwide marketing rights for Pliaglis to Galderma, and licenses have been issued in 14 of the 16 European cou
- AcneFree Products with Micro-Benzoyl Peroxide Now Availablehttps://practicaldermatology.com/news/20130430-acnefree_products_with_micro-benzoyl_peroxide_now_available/2459553/Formulated with Advanced Micro-Benzoyl Peroxide, new AcneFree Clear Skin Products from Valeant Consumer Products are formulated to effectively target acne with less irritation. Three kits are available: The AcneFree 24 Hour Acne Clearing System (AcneFree
- Ipsen's Dysport Approved for Use in Canadahttps://practicaldermatology.com/news/20130418-ipsens_dysport_approved_for_use_in_canada/2459560/Health Canada granted a marketing authorization for Dysport (Botulinum toxin type A for injection) for the temporary improvement in the appearance of moderate to severe frown lines (glabellar lines) in adult patients younger than 65 years of age. Medicis Aesthetics Canada, a division of Valeant Phar
- BTL Aesthetics Introduces Exilis Elitehttps://practicaldermatology.com/news/20130415-btl_aesthetics_introduces_exilis_elite/2459563/BTL Aesthetics recently introduced the Exilis ELITE, its next stage device for reducing wrinkles and treating skin laxity of the face and body. Optimizing the dynamic monopolar radiofrequency (RF) technology of the original Exilis system, the new ELITE platformoptimizes the monopolar radiofrequency
- Promius Pharma Introduces Zenatane and “The Promius Promise”https://practicaldermatology.com/news/20130412-promius_pharma_introduces_zenatane_and_the_promius_promise/2459565/Promius Pharma, LLC announced the introduction of Zenatane (Isotretinoin) Capsules, a newly approved isotretinoin option for patients with severe, recalcitrant, nodular acne. Zenatane will be supported by The Promius Promise, a pharmacy serv
- World's Most Valuable Cosmetics Brands Revealedhttps://practicaldermatology.com/news/20130410-worlds_most_valuable_cosmetics_brands_revealed/2459566/Brand Finance released its annual study of the top 50 most valuable cosmetics brands. Despite a very slight brand value fall, Olay holds its dominant position at the top of the BrandFinance Cosmetics 50 table, with a value of US$11.7 billion. However, Olay's lead at the top has shrunk from US$4 bill
- Obagi Fate Uncertain as New Details Emergehttps://practicaldermatology.com/news/20130403-obagi_fate_uncertain_as_new_details_emerge/2459573/Following a bidding war with rival Merz Pharma Group, Valeant Pharmaceuticals appears set to acquire Obagi Medical Products. Valeant's original offer came in March, when the company announced that it would acquire Obagi at $19.75 per share, in a deal worth approximately $344 million. Then, in early
- Merz to Absorb Costs of New Excise Tax on Certain Medical Deviceshttps://practicaldermatology.com/news/20130321-merz_to_absord_costs_of_new_excise_tax_on_medical_devices/2459580/Merz Aesthetics announced that it does not intend to raise prices on medical devices, despite the new excise tax on the sale of certain medical devices of about 2.3 percent now going into effect, per the Patient Protection and Affordable Care Act. In a statement to clients and potential clients, Mer
- Valeant Pharmaceuticals to Acquire Obagi Medical Products for Approximately $344 Millionhttps://practicaldermatology.com/news/20130320-valeant_pharmaceuticals_to_acquire_obagi_medical_products_for_approximately_360_million/2459581/Valeant Pharmaceuticals has entered into an agreement to acquire Obagi Medical Products. The transaction values Obagi common stock at approximately $344 million and was unanimously approved by the Obagi Board of Directors. Under terms of the merger agreement, Valeant will commence a tender offer for